MICROSIGX

Our platform technologies are driving new solutions for early disease detection

Discovery Platform

MicroSigX holds a comprehensive and unique databank for unparalleled microbiome discoveries and insights

1. Comprehensive clinical samples with metadata

Over 8,000 consistently analysed stool samples with over 1000 longitudinal metadata points per sample in health and diseases.

2. Advanced bioinformatic and AI-driven analysis

Deep metagenomic analysis coupled with machine-learning models to identify species, strains, genes and functional pathways across eight common diseases to inform product development

3. Discovery of disease-specific and highly accurate microbial signatures

Identify reliable signals by combining in-house and public profiles to achieve the most consistent microbial taxonomy and functional insights

4. Integrative analysis of host-microbe relationships

Extensive metadata including medical history, drugs, diet and lifestyle enables robust insights into identification of truly health- or disease-promoting associated species

5. Partnership with world-leading R & D Centers

Close partnership with the Microbiota-I Center (MagIC) to continuously expand the databank for data-driven discovery and product opportunities

Diagnostic Platform

“Our proprietary microbial biomarkers are non-invasive, biologically relevant, and disease-specific.”

MicroSigX’s biomarker discovery platform utilizes in-depth metagenomic analysis of large human microbial datasets and in-house proprietary machine-learning approaches to identify microbiome signatures specific to different human diseases with high accuracy

1. Advanced sequencing and proprietary algorithms

MicroSigX’s core diagnostic technology transforms metagenomic-sequencing derived-microbial signals into proprietary algorithms to predict risk of diseases

2. At-home stool sample collection

Simple sampling method preserves quality of microbial community profile at room temperature, ensuring convenient storage and transport

3. Development of PCR-based technologies for disease risk assessment

Transforming untargeted metagenomic detection into targeted-PCR approaches and optimizing PCR technologies for maximum accuracy

4. Discovery, validation and real-life testing

MicroSigX’s patented core PCR and metagenomics technologies have been extensively validated, demonstrating unparalleled performance in multiple validation and real-life settings. Some of these technologies are poised to enter clinical trials for regulatory approval as first-in-class in vitro diagnostics.

MICROSIGX’s pioneering diagnostic technology is transforming the detection and understanding of microbiome-related diseases, enabling earlier, more accurate, and non-invasive approaches to improving human health.

Strategic Partners

Featured in

Global Publications & Awards

Education Articles

Bacterial metabolism center stage in the Light Lab

While a postdoc at UC Berkeley, Dr. Light's work illuminated the role of flavin-type extracellular electron transfer in driving energy metabolism in Gram-positive bacteria. His earlier research has looked…

Microbiome

2022-06-09

Microbiome, Bacteria

MBL's Jessica Mark Welch studies the cuttlefish microbiome

2020-06-09

Microbiome, Bacteria

MBL's Jessica Mark Welch studies the cuttlefish microbiome

2020-06-09

Microbiome, Bacteria

MBL's Jessica Mark Welch studies the cuttlefish microbiome

2020-06-09

Microbiome, Bacteria

MBL's Jessica Mark Welch studies the cuttlefish microbiome

2020-06-09

Scholarly Interview

Bacterial metabolism center stage in the Light Lab

2020-06-09

Bacterial metabolism center stage in the Light Lab

2020-06-09

Bacterial metabolism center stage in the Light Lab

2020-06-09

VIEW ALL

Partner with Us

If you are interested to join us in world-leading gut microbiome research and development, we'll help you find the right investment or partnership within our innovative platforms.

Speak with our team